Clinical outcomes in the diabetes cohort of the international verapamil SR-trandolapril study

Hypertension

Volumn 44, Issue 5, 2004, Pages 637-642

  Bakris, George L ^a,g   Gaxiola, Efrain ^b   Messerli, Franz H ^c   Mancia, Giuseppe ^d   Erdine, Serap ^e   Cooper DeHoff, Rhonda ^f   Pepine, Carl J ^f  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Instituto Cardiovascular de Guadalajara   (Mexico)

^c OCHSNER CLINIC FOUNDATION   (United States)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e ISTANBUL UNIVERSITY   (Turkey)

^f UNIVERSITY OF FLORIDA   (United States)

^g RUSH UNIVERSITY   (United States)

Author keywords

Blood pressure; Calcium antagonists; Coronary artery disease; Diabetes mellitus

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; HYDROCHLOROTHIAZIDE; TRANDOLAPRIL; VERAPAMIL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNITED STATES; WHEEZING;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VERAPAMIL;

EID: 7244257384     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000143851.23721.26     Document Type: Article

References (28)

1. Standards of medical care in diabetes. Diabetes Care. 2004;27(suppl 1):S15-35.
2. Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection. Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
4. Turnbull F. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
5. ALLHAT Officers and Coordinators, ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc. 2002;288:2981-2997.
6. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE Study). J Hypertens. 2003;21:1563-1574.
7. Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J. The effects of verapamit, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. J Hum Hypertens. 1989;3:35-39.
8. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:1004-1010.
9. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905-912.
10. Ding YA, Chou TC, Lin KC. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension. J Hum Hypertens. 1994;8:273-278.
11. Hansen JF. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol. 1990;66:779-785.
12. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. J Am Med Assoc. 2003;290:2805-2816.
13. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
14. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J. 2003;146:848-853.
15. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA Study). Lancet. 2003;362:782-788.
16. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker- based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091-2096.
17. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. J Am Med Assoc. 2003;289:2073-2082.
18. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. J Am Med Assoc. 2003;290:199-206.
19. Singer GM, Izhar M, Black HR. Guidelines for hypertension: are quality-assurance measures on target? Hypertension. 2004;43:198-202.
20. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
21. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79:379-384.
22. Lofgren I, Herron K, Zern T, West K, Patalay M, Shachter NS, Koo SI, Fernandez ML. Waist circumference is a better predictor than body mass index of coronary heart disease risk in overweight premenopausal women. J Nutr. 2004;134:1071-1076.
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
24. Hansson L, Zanchetti I, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S; for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
25. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? J Am Med Assoc. 1991;265:489-495.
26. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
27. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363):2049-2051.
28. Kriegsman DM, Penninx BW, van Eijk JT, Boeke AJ, Deeg DJ. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients' self-reports and on determinants of inaccuracy. J Clin Epidemiol. 1996;49:1407-1417.